aNAE-negative AML by more comprehensive immunophenotype analysis.
The MTCP1 oncogene modifies T-cell homeostasis before leukemogenesis in transgenic mice Leukemia (2007) T-cell prolymphocytic leukemia (T-PLL) is a malignant hemopathy with a mature T-cell phenotype. It occurs in elderly people and is characterized by an aggressive tumoral syndrome with lymphocytosis, lymphadenopathy, hepatosplenomegaly and skin lesions. The prognosis is poor, with a median survival of approximately 9 months. Prolymphocytes are larger than lymphocytes and have a high nucleocytoplasmic ratio, a basophilic cytoplasm devoid of granules and a single prominent nucleus. The immunophenotype is that of post-thymic T lymphocytes, mainly CD4 þ CD8 À (60%), CD4 þ CD8 þ (25%) or rarely CD4 À CD8 þ . 1 The characterization of recurrent chromosomal aberrations associated with T-PLL allowed the identification of a novel oncogene family: the MTCP1/TCL1 family. 2, 3 The juxtaposition of these genes to the TCRa or TCRb loci, presumably during the V(D)J recombination, results in an increase in their expression in the T-cell lineage. The prevailing view of the MTCP1/TCL1 protein function is their primary involvement in the AKT signal-transduction pathway. However, the mechanism by which MTCP1/TCL1 proteins augment AKT activity remains incompletely resolved. The oncogenic properties of MTCP1 and TCL1 were demonstrated in animal models. Transgenic mice overexpressing MTCP1 or TCL1 in their T-cell lineage developed clonal proliferation of mature CD8 þ T-cells resembling the human T-PLL. 4, 5 In order to understand the cellular mechanism leading to leukemia, we first seek to define the immunological nature of seven CD4 À CD8 þ leukemia from MTCP1 transgenic mice (Gritti et al. 4 and unpublished data). The immunophenotype was analyzed by flow cytometry for the CD25, CD69, CD44, CD122, Ly6C, CD27 and CD62L differentiation markers. In all cases, the majority of leukemic cells were CD44 HI CD122 HI Ly6C þ CD27 þ , and CD62L þ in tested cases (Figure 1 ), a phenotype similar to that of CD8 central memory cells. 6 In two cases, this population coexisted with a CD44 LOW Ly6C þ CD62L þ and CD44 HI Ly6C À CD62L À subpopulations, respectively. None of the five tumors tested was positive for CD25, whereas CD69 was highly expressed by only one of the seven tumors, heterogeneous in three cases and not expressed at all in the remaining three (Table 1) . These results indicated that mice overexpressing MTCP1 developed a hemopathy with a CD8 central memory phenotype in most cases.
To explore the natural history of leukemogenesis in MTCP1 transgenic mice, we next examined the evolution of the CD8 memory T-cell population during aging. Blood samples were collected from two independent lines of MTCP1 transgenic mice (F3-TG and F4-TG), at different times before the emergence of the leukemia (up to 15 months), and compared with sibling controls (F3-WT and F4-WT). Accordingly, a series of 93 blood samples (44 WT and 49 TG) was stained with anti-CD4, -CD8, -CD44 and -CD122 antibodies, and the proportion of naïve and memory T lymphocyte subpopulations was determined by flow cytometry. Results from F3 and F4 mice were similar (Figure 2) , and therefore were pooled in the subsequent analyses. No significant difference was observed between TG and WT animals less than 5 months old. However, the proportion of To investigate whether the enlarged CD8 memory phenotype T cells in MTCP1 transgenic mice had a clonal origin, we analyzed the TCR Vb repertoire of this population by flow cytometry using a set of nine anti-Vb antibodies recognizing approximately 80% of the TCR repertoire. Splenocytes from four MTCP1 transgenic mice and three controls were analyzed at 7 months: the age at which the CD8m were twice more abundant in MTCP1 transgenic than in control mice (35.674.5 versus 16.474.2%, po10
À2
). CD8m expressed 1.4-fold (po10
À3
) more Vb5 and Vb8 than that of CD8na in both MTCP1 transgenic and control mice (Figure 3) , showing a skewed expression of some Vb depending on the differentiation state of cells. Surprisingly, the distribution of the Vb repertoire in all CD8 subpopulations was similar in MTCP1 transgenic mice and their controls. In particular, no skewed representation of Vb families was observed in the CD8 þ CD44 HI population from MTCP1 transgenic mice. These results indicated that the enlarged CD8 T cells, with a memory phenotype identified in MTCP1 transgenic mice, were not due to mono or oligoclonal cellular expansions. Therefore, the initial effect of MTCP1 overexpression in the T cell compartment is to perturb CD8 homeostasis. The clonal leukemic disease would then arise from this expanded population, presumably through secondary genetic events.
Cellular behavior changes were then investigated in young transgenic mice (before significant changes in the lymphoid subpopulations) by in vitro assays. Assays were used to explore T-cell proliferation and activation induced by TCR represented as open circle and triangle, respectively). These animals were analyzed at different ages before the emergence of the leukemia, from 52 days until 415 days after birth as indicated on abscissa. Cells were stained with FITC-conjugated CD44, PE-conjugated CD8a, APCconjugated CD4 and biotin-conjugated CD122 detected with CyCconjugated streptavidin.
Letters to the Editor engagement, survival to growth factor deprivations, resistance to apoptosis induced by CD3 re-stimulation and IL15-induced proliferation (indicative of self-renewal properties of CD8m cells). However, no significant difference was found in T cells from transgenic mice as compared with their control siblings. These negative results contrasted with the abnormalities in cellular behavior of untransformed T cells from TCL1 transgenic mice. 7 These differences are surprising, given that TCL1 and MTCP1 belong to the same oncogene family and share biochemical and biological properties, but may result from subtle differences between TCL1 and MTCP1 oncogenic functions, or from different expression levels and patterns of these transgenes.
MTCP1 and TCL1 transgenic mice develop leukemia with many similarities to human prolymphocytic leukemia. 4, 5 However, among observed differences, human T-PLLs have most frequently a CD4 þ CD8 À phenotype (2/3 of cases), 1 whereas most murine leukemia are CD4 À CD8 þ in the MTCP1 and TCL1 transgenic models. 4, 5 One hypothesis is that bias toward CD8 phenotype in mice is due to a stronger response of this population to T-cell stimulation. 8 Expression analyses of naïve and memory markers in the human T-PLLs also showed that these leukemia have a memory CD45RA À CD45RO þ CD29 þ phenotype. 1 These observations indicate that, both in humans and in mice, overexpression of MTCP1/TCL1 oncogene family members in T cell lineage generally leads to the development of T-PLL with a memory phenotype. However, these phenotypes are often more complex in human T-PLLs, with a frequent 'hybride' CD45RA þ CD45RO þ CD29 þ phenotype, 1 for which no physiological counterpart is known. It is possible that some human T-PLLs may result from transformation at an earlier stage than in the mouse models. The CD4 þ CD8 þ phenotype observed in approximately 25% of the human cases may support such a hypothesis. 1 Here, we demonstrate an early dysfunction in the homeostasis of CD8 T cells resulting from an overexpression of MTCP1 in the murine T-cell lineage. The oncogenic effects of MTPC1 could therefore result from an increase in the target population for malignant transformation. Identification of the earliest step of the malignant T cell transformation induced by MTCP1 is important for understanding the cellular dysfunctions leading to leukemogenesis. Figure 3 Polyclonal nature of the CD8 þ CD44 HI CD122 HI memory phenotype population in MTCP1 transgenic mice. Splenocytes from four MTCP1 transgenic and three control 7 months old mice were stained for FITC-conjugated CD44, PE-conjugated CD8a and different biotinconjugated antibodies toward approximately 80% of TCR Vb chains (BD Pharmingen, San Diego, CA, USA) and detected with CyC-conjugated streptavidin. The distribution of the different TCR Vb chains among CD8 naïve (CD8na, defined by a CD8 þ CD44 LO phenotype) and memory (CD8m, defined by a CD8 þ CD44 HI phenotype) T-cell populations is shown (in %). In the upper right panel, the proportion of CD44 HI CD122
HI memory phenotype cells among CD8 T-cell population of the MTCP1 transgenic mice and the controls is shown.
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Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12
Leukemia ( Mutations of the nucleophosmin gene (NPM1) have been described as the single most frequent abnormality in adult patients with acute myeloid leukemia (reviewed in Falini et al. 1 ). These mutations cluster in exon 12, coding for the COOHterminal region of NPM1 and always induce a net insertion of four bases. The consecutive frameshift results in an elongated protein which contains an additional nuclear export signal and leads to an abnormal cytoplasmic localization of the protein. 2 The most common type of mutation (type A), the duplication of the four bases TCTG, is found in approximatley 80% of all adult cases, but more than 40 additional mutations have been described. 2, 3 In adult AML, NPM1 mutations were found to be associated with a distinct subgroup of patients with particular clinical (female sex, high WBC counts), morphological (cup-like morphology, lack of CD34 expression) and cytogenetic (normal karyotype) characteristics. 1 In addition, several studies in adults have shown that NPM1-mutations represent an independent good prognostic marker, but only if not associated with FLT3-ITD mutations.
1 Few data exist on the incidence and relevance of NPM1-mutations in children. The study by Cazzaniga et al. 4 is the only report specifically investigating NPM1-mutations in pediatric AML. They found a low overall prevalence of 6.5% (7/107 patients), and showed that cases with NPM1 mutation were older and frequently had a normal karyotype. Only one additional study referred to NPM1-mutations in children, but did not further specify the pediatric patients. 5 To gain further insight in the role of NPM1 in pediatric AML, we have investigated NPM1 mutations in a cohort of 75 children and young adults with AML (including one patient borderline to advanced MDS) treated in the AML98 and AML2004 protocols of the Berlin-Mü nster-Frankfurt (BFM) study group. 6 DNA was extracted from cryopreserved cells and screened for NPM1 and FLT3 mutations using high resolution fragment analysis. 7 Overall, 9/75 (12%) samples showed NPM1-mutations. As reported in adults, 1 children with NPM1-mutations predominantly had a normal karyotype (NPM1-mut: 8/9; 89% compared to NPM1-wt: 30/56; 54%; P ¼ 0.069). Patients with NPM1 mutations were older (median age 13.2 vs 10.4 years) and -as shown in adultspredominantly had female sex (56 vs 33%). They frequently also showed an FLT3-ITD mutation (44 vs 23%), but due to the small number of cases, none of these associations was significant. Interestingly, all patients with NPM1 mutations are alive in remission (except one, who died before starting treatment from cerebral bleeding), irrespective of the FLT3-ITD status, but this has clearly to be interpreted with caution, due to the small number of patients.
We also sequenced all positive cases. Interestingly, only one of the patients had mutation A, the predominant variant in adults. The most common mutation in this pediatric group was type B (6/9; 67%; Table 1 ). As Cazzaniga et al. 4 also found only 1/7 cases with mutation A, we asked whether this distribution was by chance and compared the mutational spectrum of 434 recently analyzed adult patients with NPM1-mutations with the pediatric cases. The comparison of type A mutations (323/434 adults and 1/9 children) and non-type A mutations (111/434 adults and 8/9 children) showed a highly significant difference in the prevalence of this alteration (P ¼ 0.0002; Fisher's exact test). A comparison of the age of the adult patients with type A and non-type A mutations indicated that patients with type A mutations had a trend for a higher median age (60 years), compared to cases with non-A mutations (median age 57 years; P ¼ 0.068). When analyzed in age groups (below and above 50 years), the non-type A mutation frequency was 32% below the age of 50 and only 23% above this age (P ¼ 0.015). Abbreviations: allo SCT, allogeneic stem cell transplantation, F, female; M, male; MDS, myelodysplastic syndrome; Neg., negative; Pos., positive. a This patient was borderline to MDS-RAEB (20% blasts in the bone marrow).

